4.3 Article

Blocking the formation of radiation-induced breast cancer stem cells

期刊

ONCOTARGET
卷 5, 期 11, 页码 3743-3755

出版社

IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.1992

关键词

Breast Cancer; Radiation; Cancer Stem Cells; NF-kappaB Stemness genes

资金

  1. NIH [RO3 CA141086, R01-1CA138188, 2P50CA121973-06, 7R01CA110249-06]
  2. Susan G. Komen Postdoctoral Fellowship [KG111486]

向作者/读者索取更多资源

The goal of adjuvant (post-surgery) radiation therapy (RT) for breast cancer (BC) is to eliminate residual cancer cells, leading to better local tumor control and thus improving patient survival. However, radioresistance increases the risk of tumor recurrence and negatively affects survival. Recent evidence shows that breast cancer stem cells (BCSCs) are radiation-resistant and that relatively differentiated BC cells can be reprogrammed into induced BCSCs (iBCSCs) via radiation-induced re-expression of the stemness genes. Here we show that in irradiation (IR)-treated mice bearing syngeneic mammary tumors, IR-induced stemness correlated with increased spontaneous lung metastasis (51.7%). However, IR-induced stemness was blocked by targeting the NF-kappa B- stemness gene pathway with disulfiram (DSF) and Copper (Cu2+). DSF is an inhibitor of aldehyde dehydrogenase (ALDH) and an FDA-approved drug for treating alcoholism. DSF binds to Cu2+ to form DSF-Cu complexes (DSF/Cu), which act as a potent apoptosis inducer and an effective proteasome inhibitor, which, in turn, inhibits NF-kappa B activation. Treatment of mice with RT and DSF significantly inhibited mammary primary tumor growth (79.4%) and spontaneous lung metastasis (89.6%) compared to vehicle treated mice. This anti-tumor efficacy was associated with decreased stem cell properties (or stemness) in tumors. We expect that these results will spark clinical investigation of RT and DSF as a novel combinatorial treatment for breast cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Oncology

Cancer Cell Metabolism Reprogramming and Its Potential Implications on Therapy in Squamous Cell Carcinoma of the Head and Neck: A Review

Francesco Perri, Giuseppina Della Vittoria Scarpati, Monica Pontone, Maria Luisa Marciano, Alessandro Ottaiano, Marco Cascella, Francesco Sabbatino, Agostino Guida, Mariachiara Santorsola, Piera Maiolino, Ernesta Cavalcanti, Giulia Togo, Franco Ionna, Francesco Caponigro

Summary: Metabolic reprogramming is a common phenomenon in various solid tumors, including head and neck cancers. Analyzing the genetic and biological mechanisms of metabolic reprogramming in squamous cell carcinomas of the head and neck can provide potential therapeutic strategies to counteract it.

CANCERS (2022)

Article Oncology

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy

Sjoerd P. F. T. Nota, David O. Osei-Hwedieh, David L. L. Drum, Xinhui Wang, Francesco Sabbatino, Soldano Ferrone, Joseph H. Schwab

Summary: This study assessed the expression of CSPG4 in human chondrosarcoma and the effectiveness of CSPG4-specific CAR T cells in killing chondrosarcoma cells in vitro. The results showed medium to high expression of CSPG4 in conventional chondrosarcoma and demonstrated the effectiveness of CSPG4-targeted CAR T cells in killing CSPG4-positive chondrosarcoma tumors.

FRONTIERS IN ONCOLOGY (2022)

Review Chemistry, Multidisciplinary

Bibliometric and Visual Analysis of the Scientific Literature on Percutaneous Electrical Nerve Stimulation (PENS) for Pain Treatment

Federica Monaco, Sergio Coluccia, Arturo Cuomo, Davide Nocerino, Daniela Schiavo, Gilda Pasta, Francesca Bifulco, Pasquale Buonanno, Vittorio Riccio, Marianna Leonardi, Francesco Perri, Alessandro Ottaiano, Francesco Sabbatino, Alessandro Vittori, Marco Cascella

Summary: This bibliometric study analyzed the utilization of percutaneous electrical nerve stimulation (PENS) for pain treatment. The study found that while there is an increasing trend in the number of publications on this topic and the publication of articles in high impact factor journals, there is a need for stronger scientific collaborations between researchers and institutions from different countries.

APPLIED SCIENCES-BASEL (2023)

Article Medicine, General & Internal

Survival and Toxicities of Metastatic Colorectal Cancer Patients Treated with Regorafenib before TAS-102 or Vice Versa: A Mono-Institutional Real-Practice Study

Alessandro Ottaiano, Mariachiara Santorsola, Francesco Perri, Vincenza Granata, Marco Cascella, Francesco Sabbatino, Guglielmo Nasti

Summary: This study compared the different treatment sequences of TAS-102 first or regorafenib first in patients with metastatic colorectal cancer. The results showed a significant difference in overall survival, with a median survival of 4.5 months for the TR sequence and 3.0 months for the RT sequence.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Pharmacology & Pharmacy

Bispecific Antibodies: A Novel Approach for the Treatment of Solid Tumors

Luigi Liguori, Giovanna Polcaro, Annunziata Nigro, Valeria Conti, Carmine Sellitto, Francesco Perri, Alessandro Ottaiano, Marco Cascella, Pio Zeppa, Alessandro Caputo, Stefano Pepe, Francesco Sabbatino

Summary: Advancement in sequencing technologies has led to the development of targeted therapies for cancer treatment. However, the long-term control of cancer progression remains challenging due to the development of resistance. Bispecific antibodies (bsAbs), which target multiple components involved in cancer pathways simultaneously, have emerged as a potential solution to overcome off-target resistance. This review provides an overview of the classification, design, mechanisms of action, and clinical evidence of bsAbs for the treatment of solid malignancies.

PHARMACEUTICS (2022)

Article Medicine, General & Internal

Hypertension, type 2 diabetes, obesity, and p53 mutations negatively correlate with metastatic colorectal cancer patients' survival

Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Francesco Perri, Marco Cascella, Francesco Sabbatino, Maurizio Capuozzo, Vincenza Granata, Silvia Zappavigna, Angela Lombardi, Marianna Scrima, Nadia Petrillo, Monica Ianniello, Marika Casillo, Oreste Gualillo, Guglielmo Nasti, Michele Caraglia, Giovanni Savarese

Summary: This study examines the impact of hypertension, type 2 diabetes, weight, and p53 mutations on the prognosis of metastatic colorectal cancer patients. Patients were diagnosed with type 2 diabetes according to ADA criteria and classified hypertension based on ACC/AHA guidelines. Overall survival analysis showed that diabetic patients had lower disease control rates and that the concurrent presence of type 2 diabetes, BMI, and hypertension was an independent prognostic factor. P53 mutations were found to be associated with BMI and had a negative impact on prognosis, suggesting a complex relationship between metabolism and cancer occurrence.

FRONTIERS IN MEDICINE (2023)

Review Oncology

Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer

Francesco Perri, Francesco Sabbatino, Alessandro Ottaiano, Roberta Fusco, Michele Caraglia, Marco Cascella, Francesco Longo, Rosalia Anna Rega, Giovanni Salzano, Monica Pontone, Maria Luisa Marciano, Arianna Piccirillo, Massimo Montano, Morena Fasano, Fortunato Ciardiello, Giuseppina Della Vittoria Scarpati, Franco Ionna

Summary: Epstein Barr virus (EBV) is implicated in the development of both solid and hematologic malignancies, particularly nasopharyngeal carcinomas (NPCs). Viral proteins produced during the latent phase of EBV in epithelial cells can induce or promote carcinogenesis and can be targeted by immunotherapy strategies. The use of check-point inhibitors has shown promising results in treating EBV-associated carcinomas.

CANCERS (2023)

Review Oncology

Oligo-Metastatic Cancers: Putative Biomarkers, Emerging Challenges and New Perspectives

Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Anna Maria Trotta, Francesco Izzo, Francesco Perri, Marco Cascella, Francesco Sabbatino, Vincenza Granata, Marco Correra, Luca Tarotto, Salvatore Stilo, Francesco Fiore, Nicola Martucci, Antonello La Rocca, Carmine Picone, Paolo Muto, Valentina Borzillo, Andrea Belli, Renato Patrone, Edoardo Mercadante, Fabiana Tatangelo, Gerardo Ferrara, Annabella Di Mauro, Giosue Scognamiglio, Massimiliano Berretta, Maurizio Capuozzo, Angela Lombardi, Jerome Galon, Oreste Gualillo, Ugo Pace, Paolo Delrio, Giovanni Savarese, Stefania Scala, Guglielmo Nasti, Michele Caraglia

Summary: Oligometastatic disease is a condition in which cancer spreads to only a few distant sites, and it is associated with a more favorable prognosis compared to polymetastatic disease. Recent studies have identified specific molecular and genetic features that underlie the oligometastatic phenotype, suggesting the potential for personalized therapies. This scoping review highlights new clinical, biological, and methodological challenges in understanding and treating oligometastatic disease.

CANCERS (2023)

Review Health Care Sciences & Services

Long COVID: Clinical Framing, Biomarkers, and Therapeutic Approaches

Valeria Conti, Graziamaria Corbi, Francesco Sabbatino, Domenico De Pascale, Carmine Sellitto, Berenice Stefanelli, Nicola Bertini, Matteo De Simone, Luigi Liguori, Ilenia Di Paola, Maddalena De Bernardo, Angela Tesse, Nicola Rosa, Pasquale Pagliano, Amelia Filippelli

Summary: Long COVID or post-COVID-19 syndrome (PCS) refers to the development of persistent symptoms and/or complications in patients diagnosed with COVID-19. The pathogenesis and course of this syndrome are influenced by factors such as age, sex/gender, and pre-existing conditions. The lack of precise diagnostic and prognostic biomarkers complicates the clinical management of patients. This review aims to summarize recent evidence on the factors influencing PCS, possible biomarkers, and therapeutic approaches.

JOURNAL OF PERSONALIZED MEDICINE (2023)

Article Oncology

BRAF p.V600E mutation as a molecular boundary between genuine oligo-repeated and poly-metastatic disease in colorectal cancer

Alessandro Ottaiano, Mariachiara Santorsola, Luisa Circelli, Monica Ianniello, Marika Casillo, Nadia Petrillo, Francesco Sabbatino, Marco Cascella, Francesco Perri, Maurizio Capuozzo, Vittorio Albino, Vincenza Granata, Francesco Izzo, Annabella Di Mauro, Massimiliano Berretta, Raffaella Ruggiero, Oreste Gualillo, Roberto Sirica, Guglielmo Nasti, Giovanni Savarese

NEOPLASIA (2023)

Article Medicine, General & Internal

Different Prognostic Role of Soluble PD-L1 in the Course of Severe and Non-Severe COVID-19

Francesco Sabbatino, Pasquale Pagliano, Carmine Sellitto, Berenice Stefanelli, Graziamaria Corbi, Valentina Manzo, Emanuela De Bellis, Luigi Liguori, Francesco Antonio Salzano, Stefano Pepe, Amelia Filippelli, Valeria Conti

Summary: This study investigates the potential of sPD-L1 as a prognostic biomarker for COVID-19. The results suggest that sPD-L1 promotes immune escape in the early phase of COVID-19, but may act to dampen excessive immune responses later. Additionally, there is a correlation between lymphocyte number and length of stay and inflammatory markers.

JOURNAL OF CLINICAL MEDICINE (2023)

Review Oncology

KRAS p.G12C Mutation in Metastatic Colorectal Cancer: Prognostic Implications and Advancements in Targeted Therapies

Alessandro Ottaiano, Francesco Sabbatino, Francesco Perri, Marco Cascella, Roberto Sirica, Renato Patrone, Maurizio Capuozzo, Giovanni Savarese, Monica Ianniello, Nadia Petrillo, Luisa Circelli, Vincenza Granata, Massimiliano Berretta, Mariachiara Santorsola, Guglielmo Nasti

Summary: This review discusses the prognostic significance of the KRAS p.G12C mutation in metastatic colorectal cancer and highlights its potential as a promising therapeutic target. The aim is to increase awareness of the factors that can influence the clinical, prognostic, and therapeutic implications associated with distinct mutations within the same protein.

CANCERS (2023)

Article Biochemistry & Molecular Biology

Prior Anti-Angiogenic TKI-Based Treatment as Potential Predisposing Factor to Nivolumab-Mediated Recurrent Thyroid Disorder Adverse Events in mRCC Patients: A Case Series

Luigi Liguori, Angelo Luciano, Giovanna Polcaro, Alessandro Ottaiano, Marco Cascella, Francesco Perri, Stefano Pepe, Francesco Sabbatino

Summary: In patients with metastatic renal cell carcinoma, prior treatment with anti-angiogenic tyrosine kinase inhibitors (TKIs) significantly increases the risk of immune checkpoint inhibitor (ICI)-mediated recurrent thyroid disorder adverse events (TDAEs) without modifying their clinical characteristics.

BIOMEDICINES (2023)

Review Biology

From Chaos to Opportunity: Decoding Cancer Heterogeneity for Enhanced Treatment Strategies

Alessandro Ottaiano, Monica Ianniello, Mariachiara Santorsola, Raffaella Ruggiero, Roberto Sirica, Francesco Sabbatino, Francesco Perri, Marco Cascella, Massimiliano Di Marzo, Massimiliano Berretta, Michele Caraglia, Guglielmo Nasti, Giovanni Savarese

Summary: Cancer is a complex disease characterized by aberrant cellular behaviors and genetic variances, leading to tumor heterogeneity. This heterogeneity poses challenges in cancer prognosis and treatment, and understanding and quantifying it is crucial. This review emphasizes the significance of comprehending tumor heterogeneity to raise awareness about this elusive characteristic of cancer.

BIOLOGY-BASEL (2023)

Article Biochemistry & Molecular Biology

Does burning fat make tumor immune hot? Discovery of CD47 overexpression by radiation induced fatty acid oxidation

Nian Jiang, Bowen Xie, Ming Fan, Jian Jian Li

Summary: Although the major cellular energy driving tumor metastasis after anti-cancer radiotherapy is unknown, accumulating evidence suggests that cancer cells can reactivate mitochondrial oxidative respiration to meet the increased cellular fuel demand for repairing and surviving anti-cancer radiation. This dynamic metabolic rewiring may play a key role in cancer therapy resistance and metastasis.

GENES & DISEASES (2023)

暂无数据